Archive for the ‘Uncategorized’ Category

Just Issued! Health Care Innovation Awards Round Two: $1,000,000,000 to be awarded

May 21, 2013

Health Care Innovation Awards Round Two

The Centers for Medicare & Medicaid Services (CMS) has released an Announcement for round two of the Health Care Innovation Awards. CMS will spend up to $1 billion for awards and evaluation of projects  that test new payment and service delivery models that will deliver better care and lower costs.

 [solicitation] [more information]

Funding Opportunity Announcement

The second round of the Health Care Innovation Awards will support public and private organizations in four defined areas that have a high likelihood of driving health care system transformation and delivering better outcomes.

Specifically, in this second round, CMS is seeking proposals in the following categories:

  • Models that are designed to rapidly reduce Medicare, Medicaid, and/or CHIP costs in outpatient and/or post-acute settings.
  • Models that improve care for populations with specialized needs.
  • Models that test approaches for specific types of providers to transform their financial and clinical models.
  • Models that improve the health of populations – defined geographically (health of a community), clinically (health of those with specific diseases), or by socioeconomic class – through activities focused on engaging beneficiaries, prevention (for example, a diabetes prevention program or a hypertension prevention program), wellness, and comprehensive care that extend beyond the clinical service delivery setting.

In this round, CMS specifically seeks new payment models to support the service delivery models funded by this initiative. All applicants must submit, as part of their application, the design of a payment model that is consistent with the new service delivery model that they propose.

[more information]

FreeMind Expertise – Maximize yor Chances for Award

The FreeMind Group has extensive experience in assisting clients with such complex and competitive proposals. Through our methodical and proven professional process we will guide your efforts through to submission and subsequent award.

Contact Us – Talk to an Expert

To schedule a time to chat with an expert from FreeMind, please contact Carla Hamoy at:

Carla Hamoy

carla@freemindconsultants.com

617-648-0340, ext: 249

NCI Opportunities of Interest to the Innovator Community:

May 15, 2013
  1. Funding for Provocative Questions Now Available; Letters of Intent due May 20
  2. Request for Information (RFI) Regarding Opportunities for Cancer-relevant Innovative Technologies with Transformative Potential

 

Funding for Provocative Questions Now Available

The National Cancer Institute (NCI) is looking for bold new approaches to answer 24 perplexing scientific questions identified by the community. Apply for funding to find the answer to one of those questions!

Submit a Letter of Intent by May 20, 2013.
Applications are due June 20, 2013.

The Provocative Questions Initiative has assembled a list of important questions to stimulate the NCI’s research communities to use laboratory, clinical, and population sciences in especially effective and imaginative ways to answer the questions. Researchers from all sectors are invited to apply for grant funding in four thematic areas:

  • Cancer Prevention and Risk
  • Mechanisms of Tumor Development or Recurrence
  • Tumor Detection, Diagnosis, and Prognosis
  • Cancer Therapy and Outcomes

 
Please note that this is not an SBIR/STTR award, but small businesses are eligible to apply for R01 and R21 grants.

View the list of Provocative Questions and current Funding Opportunity Announcements at: provocativequestions.nci.nih.gov. If there are any questions about this initiative, please email NCIProvocativeQuestions@mail.nih.gov.

 

Request for Information (RFI) Regarding Opportunities for Cancer-relevant Innovative Technologies with Transformative Potential

The NCI invites feedback from cancer researchers, clinicians, and other interested members of the community through a Request for Information (RFI).

The purpose of the RFI is to seek input on the most important needs and promising opportunities to develop technologies with strong potential for accelerating cancer research or clinical care. NCI is interested in understanding the communities’ perspective on areas where state-of-the-art capabilities are insufficient for clinical care or to explore biological or epidemiological facets of cancer.

Responses to the RFI will be used for consideration of research priorities and may help to develop future funding opportunities for the Innovative Molecular Analysis Technologies (IMAT) Program.

Please click here for a list of currently open funding opportunities available as part of the IMAT Program. Please note that this is not an SBIR/STTR award, but small businesses are eligible to apply for R21 and R33 grants.

How to Submit a Response
Responses will be accepted through June 30, 2013 and should be marked with this RFI identifier “NOT-CA-13-009.” Responses are preferred in electronic format and should be e-mailed to nciimat@mail.nih.gov. View the RFI for additional instructions on how to respond: http://grants.nih.gov/grants/guide/notice-files/NOT-CA-13-009.html.

Join Dr. Tony Dickherber for a Town Hall
Ask questions and receive additional insight during a teleconference on May 29 at 3:00 p.m. ET. Dial 1-800-593-0693 and use the passcode “NCI.”

 

The SBIR & STTR Programs are NCI’s engine of innovation for developing and commercializing novel technologies and products to prevent, diagnose, and treat cancer. The SBIR & STTR Programs are government set-aside programs for domestic small businesses to engage in research and development that has the potential for commercialization and public benefit.

Sign up to receive updates about
SBIR & STTR funding opportunities at
sbir.cancer.gov

Research Funding Through CDRMP

May 14, 2013

The Department of Defense intends to award in aggregate $420,000,000 in research funding through the Congressionally Directed Medical Research Programs (CDRMP). [more information] [current opportunities]


CANCER – NEUROSCIENCE – MEDICAL RESEARCH PROGRAM

CDMRP Programs

Comprehensive Program Announcements are expected to be released during May to July of 2013

  • Amyotrophic Lateral Sclerosis Research Program – $7.5 million
  • Autism Research Program – $6 million
  • Bone Marrow Failure Research Program – $3.2 million
  • Breast Cancer Research Program – $120 million
  • Duchenne Muscular Dystrophy Research Program – $3.2 million
  • Gulf War Illness Research Program – $20 million
  • Lung Cancer Research Program – $10.5 million
  • Multiple Sclerosis Research Program – $5 million
  • Neurofibromatosis Research Program – $15 million
  • Ovarian Cancer Research Program – $20 million
  • Peer Reviewed Cancer Research Program – $15 million
  • Peer Reviewed Medical Research Program – $50 million
  • Peer Reviewed Orthopaedic Research Program – $30 million
  • Prostate Cancer Research Program – $80 million
  • Spinal Cord Injury Research Program – $30 million
  • Tuberous Sclerosis Complex Research Program – $6 million

 

[current opportunities]

FreeMind Expertise

Maximize yor Chances for Award

The FreeMind Group has extensive experience in assisting clients in completing and winning such complex and competitive proposals. Through our methodical and proven professional process we will guide your efforts through to submission and subsequent award.

Contact Us

Talk to an Expert

To schedule a time to chat with an expert from FreeMind, please contact Carla Hamoy at:

 

Carla Hamoy

carla@freemindconsultants.com

617-648-0340 ext. 249

Harlan Laboratories Continues Global Growth with Major Expansion of North American Facilities

May 7, 2013

For Immediate Release:

May 7, 2013

INDIANAPOLIS - Harlan Laboratories, a leading contract research organization and research models and services company, today announced the expansion of its specialty research production facilities in Indianapolis and Livermore, CA. This expansion more than doubles the number of isolators at these sites allowing Harlan to meet growing customer demand for its immunocompromised models.

 

“Our investment in these facilities underscores our commitment to providing the highest quality research models and services to investigators across the globe,” said Joe Meyer, Vice President Global Commercial Operations at Harlan Laboratories. “We will continue to expand and enhance our facilities worldwide to meet the needs of the research community in key therapeutic research areas like oncology, immunology and toxicology with consistently dependable research models, diets and supporting services.”

 

These facilities incorporate the latest technology and design advances to ensure sustained high health status research models.  The environmentally controlled breeding isolators are supported by individual air supply and HEPA filtered air handling to ensure the integrity of the colony housed within each isolator. The facilities also feature the latest state-of-the-art equipment and biosecurity measures including a watering system with automatic flushing to help prevent the unwanted proliferation of organisms, as well as a whole building redundant backup power system.

The expansion extends beyond an increase in facility footprint. Harlan Laboratories incorporated several sustainable components to the newly renovated Indianapolis and Livermore facilities.

“We designed the facilities with a dual purpose ­­- animal care and sustainability. We have incorporated energy efficient lighting and water systems, as well as designed workflows to support our biosecurity practices,” said Mike Lipke, Global Vice President of Operations at Harlan Laboratories. “We are very proud of these two additions to the Harlan network and look forward to our ability to meet increasing customer demand from these state-of-the-art facilities.”

For more information on Harlan Laboratories, visit www.Harlan.com.

About Harlan Laboratories, Inc.

Harlan Laboratories, Inc. is a leading provider of essential, pre-clinical and non-clinical contract research, research models, animal diets, and services to the pharmaceutical, biotech, medical device, agrochemical and chemical industries, as well as universities, government, and other research organizations. Our focus is on providing customers with products and services to optimize the discovery and safety of new medicines and compounds. Harlan Laboratories is a privately held company.                                           

 

DTRA Funding Opportunities- Just Issued and Rapidly Approaching!

February 22, 2013

The FreeMind Group is a BIO Business Solutions Program Member:

FreeMind

The Defense Threat Reduction Agency (DTRA) has just issued a very exciting opportunity covering a vast array of topics (see below) . The March 20th deadline is rapidly approaching, so start drafting your application today!

The FreeMind Group has extensive experience in assisting clients in completing and winning such complex and competitive proposals. Through our methodical and proven professional process we will guide your efforts through to submission and subsequent award.

To schedule a call with a representative from FreeMind please contact Carla Klein at:

(617) 648-0340, carla@freemindconsultants.com

 

 - FUNDING OPPORTUNITIES -

HDTRA1-14-CHEM-BIO-BAA, Chemical Biological Technologies Department BAA Synopsis/Solicitation FY2014 – FY2016 Program Build

  • Important deadlines:

March 20, 2013: Phase I proposal receipt deadline (Quad chart/white paper).

April 2, 2013: Phase II proposal receipt invited.

May 14, 2013: Phase II receipt deadline.

June 11, 2013: Notification of selection/non-selection.

January 14, 2014: Estimated first award date.

  • Funding: May request project period of up to 5 years with a budget appropriate for the science proposed.
  • Scope: The Chemical / Biological Technologies Department (CB), in its continuing mission, seeking new and innovative ideas for experimental and theoretical development of technologies to fill DoD requirements for chemical and biological defense.

The goal is to identify and select science and technology projects that can be transitioned to joint acquisition programs in the following topics:

 

  • Single Cell Biomarker Expression Methods/Analysis
  • Host-Based Biomarker/Assay Development
  • Bioagent Infection of In Vitro Organ Models to Develop Companion Diagnostics
  • Next-generation analytic capabilities for BSV
  • Alternate Manufacturing Processes for Recombinant Human Butyrylcholinesterase
  • Pretreatments for Chemical Nerve Agent Exposure
  • Centrally Active Nerve Agent Treatment Systems (CANATs)
  • Enabling Science: Novel Threat Research
  • Predictive Toxicology Tools for Enabling Rapid Countermeasure Development
  • Resuspension Factors and Atmospheric Persistence of CB Particulate and Aerosol Threats
  • Methods for Rapid Prediction of Agent-Substrate Interactions Including Correlation of Chemical or Biological Agent Physical Properties to Determine Underlying Mechanisms
  • Novel vaccines directed against Burkholderia pseudomallei and Burkholderia mallei
  • Vaccine Candidates for Type A Francisella tularensis
  • Vaccine Candidates for Q Fever
  • Antibody-based Prophylactic Protection against Viral Pathogens
  • Drug Discovery and Development of Therapeutics for Encephalitic Alphavirus Infections
  • Antimicrobial Development for Burkholderia pseudomallei and Multi-Drug Resistant (MDR) Strains of Bacillus Anthracis, YersiniaPestis, and Francisella Tularensis
  • CB Mobile Sensing Technology Demonstration
  • Additive Manufacturing Fabrication of Mobile Chem/Bio Sensing Platforms
  • Additive Manufacturing Replenishment of Expendable Chem/Bio Sensors
  • Enable rapid and active mitigation of the threat of bulk chemical weapon material, in the field

[Solicitation]

 

 

HDTRA1-11-16-RDIS, R&D Innovation and Systems Engineering Office Science and Technology New Initiatives - Broad agency announcement

  • Upcoming deadline: Open solicitation which consists of two phases; pre-application followed by an invitation to submit a full application. For the pre-application there is an ongoing deadline.
  • Funding: No cap on the budget. May request a project period of up to 5 years with a budget appropriate for the science proposed.
  • Scope: The directorates and offices within DTRA’s Research and Development (R&D) Enterprise identify, conduct, and deliver innovative science and technology that enable America to combat Weapons of Mass Destruction, all of which are tied to the Strategic Goals and Objectives. Specific capabilities sought in this BAA are in the technology areas of Chemical/Biological, Counter WMD, Radiation/Nuclear, Reachback and Decision Support and Treaty Verification/Compliance.

[Solicitation]

To schedule a call with a representative from FreeMind please contact Carla Klein at:

(617) 648-0340, carla@freemindconsultants.com

Indiana’s life sciences industry economic impact tops $50 billion

January 22, 2013

New statistics underscore continued growth and leadership in key areas 

 

Indianapolis, January 22, 2013 –  Indiana’s life sciences industry has a $50 billion total impact on the state’s economy, according to recently updated data gathered by the Indiana Business Research Center at the Indiana University Kelley School of Business and BioCrossroads, Indiana’s initiative for investment, development and advancement of the state’s signature life sciences strengths.

Now with a workforce of 55,000 people at nearly 2,000 companies in the areas of drugs and pharmaceuticals, medical devices and equipment, agricultural chemicals and feedstock, medical, research and testing laboratories and biologistics*, Indiana is ranked as one of the top five states in the life sciences industry – based on the highest number of employees in the sector, the highest number of companies and the highest concentration of employees (BIO/Battelle State Bioscience Industry Development Report 2012).

Indiana’s life sciences exports totaled $9.3 billion (one-third of Indiana’s total exports), ranking as the third highest in the United States, behind only California and Texas.

These companies are also continuing to discover and commercialize new products.   There were 489 patent filings for life sciences-related innovations in 2011, and 173 new products approved by the U.S. Food and Drug Administration.

“These statistics just continue to get better for us, and demonstrate across the board that the life sciences are a robust industry and a valuable driver of Indiana’s economic growth.  It is imperative that we continue the momentum, and BioCrossroads has several initiatives in progress to capitalize on our unique strengths,” said David L. Johnson, president and CEO of BioCrossroads.  “These data elevate Indiana to the same company as America’s other world-renowned centers of healthcare innovation: Massachusetts, California, North Carolina and New Jersey.”

Other key findings:

  • Indiana’s life sciences venture capital investments rose in 2012 to $64.7 million.
  • The average annual wage for a life sciences worker is now $88,504, compared to $40,272 for the average private sector wage.
  • Indiana life sciences workers earn nearly $5 billion in annual wages.

 

Indiana is home to the global headquarters for: Biomet, Cook Medical, DePuy Orthopaedics, Dow AgroSciences, Eli Lilly and Company, WellPoint, and Zimmer and the North American headquarters of Roche Diagnostics; Beckman Coulter, Boston Scientific, Covance, Express Scripts, Mead Johnson, and Medtronic have major operations located within the state.

BioCrossroads’ 2012 annual report which includes this information is available at www.biocrossroads.com

 

About BioCrossroads

BioCrossroads (www.biocrossroads.com) is Indiana’s initiative to grow, advance and invest in the life sciences, a public‑private collaboration that supports the region’s existing research and corporate strengths while encouraging new business development.  BioCrossroads provides money and support to life sciences businesses, launches new life sciences enterprises (Indiana Health Information Exchange, Fairbanks Institute for Healthy Communities, BioCrossroadsLINX, OrthoWorx and Datalys Center), expands collaboration and partnerships among Indiana’s life science institutions, promotes science education and markets Indiana’s life sciences industry.

 

Editor’s note: jpg files of graphics are available.

 

Unless otherwise noted, the most recent statistical data is from 2011.

Source: BioCrossroads/Indiana Business Research Center.

*Biologistics is a new sub-sector that BIO/Battelle added in their State Bioscience Industry Development Report 2012.  BioCrossroads included biologistics as a new sub-sector for the 2011 data represented within this news release.

Student Team Finds Sponsors for International Competition

January 5, 2013

The high school students at the McKenzie Center for Innovation and Technology in Indianapolis will be participating in the International Genetically Engineered Machine (iGEM) competition this year thanks to the generous sponsorship of Rimedion.  Based in Indianapolis, Rimedion is a gene therapy company working on unique gene therapies and associated technologies for advancing the field.   The company was founded by Dr. Ken Cornetta, Chair of Medical and Molecular Genetics for the IU School of Medicine and Director of the NIH Gene Vector Bio Repository and the IU Vector Production Facility.

The students, who participate in the Project Lead the Way curriculum, will be working with their instructor to develop a bio-reactive gel to help identify skin cancer.  Other Indiana teams will also be participating in the competition and we wish them all the best of luck!  IHIF is also helping to sponsor the McKenzie team and will be reporting on the students’ projects in the upcoming 2013 edition of BioFutures, available in March.

Safis Solutions Names New Vice President

December 10, 2012

Safis Solutions Names New Vice President
John Nadelin takes Vice President of Regulatory and Compliance role, leading Safis through the complex and evolving life sciences business.
Indianapolis, December 4, 2012: As the life sciences industry continues to transform in the face of legislative, regulatory, and economic changes, Safis Solutions continues to adapt as well. Safis today announced that John Nadelin has been named Vice President of Regulatory and Compliance. Mr. Nadelin joined Safis in January of 2010 as Director of Compliance Services. His responsibilities will continue to include ensuring client needs are served, while also managing business development activities and expanding the domain expertise within the Safis team to meet the changing needs of clients.
Mr. Nadelin brings over 25 years of life sciences industry leadership to Safis, spanning large pharma, biotech startups, and medical device firms. Some previous assignments include senior management positions in regulatory, quality, and pharmacovigilance with Pfizer, Perrigo, and Targanta.

Randy Hitchens, Senior VP of Business Development for Dermal Life LLC noted, “We have been continually impressed with the leadership John brings to the Safis team. Safis has helped Dermal Life navigate the FDA approval process for prescription and OTC skin care products, and react quickly to challenges along the way. We look forward to continuing to work with the Safis Solutions as our regulatory and quality partner.”

Contact: Thomas Stergar II
Safis Solutions, LLC
Phone: (317) 777-6203
Fax: (317) 777-6193
342 Massachusetts Avenue
Indianapolis, IN 46204
http://www.safis-solutions.com
SAFIS SOLUTIONS, LLC

John Lechleiter: Keys to Indiana’s success | Indianapolis Star | indystar.com

November 27, 2012

John Lechleiter: Keys to Indiana’s success | Indianapolis Star | indystar.com.

5:39 PM, Nov 23, 2012

You might be surprised to know that Indiana is in the top five among all states in employment in the life sciences, or that only two states — California and Texas — have more life sciences exports than Indiana, or that more people in Indiana work in life sciences than in the automobile industry.

Yes, the life sciences are Indiana’s greatest economic success story of recent times. But Indiana’s continued leadership in life sciences is in serious jeopardy. We can’t afford to squander the advantage we’ve created. We need to take action — now.

For all our progress in the life sciences, regions across the U.S. and around the world have their eyes on the same goal, even as some of our strongest competitors are taking further bold steps to distance themselves from the pack.

Building on the success we’ve achieved will require a far larger — and much more ambitious — shared effort among Indiana’s life sciences companies, research universities and state government.

The key question facing us today is: What is it going to take for Indiana to maintain leadership in the life sciences and to compete effectively on the world stage? Let me lay out three imperatives — and at least one bold idea:

The first imperative is a concerted effort to attract and retain the most talented people we can find. This is fundamental to our continued success.

We need to start by focusing on better educating our own citizens. To cite just one relevant indicator, the latest test scores from the U.S. Dept. of Education showed only 33 percent of Indiana 8th graders to be proficient in science. We need a sustained, intense effort in K-12 education to improve performance. We must also ensure that Indiana’s business environment — currently ranked fifth best on Chief Executive magazine’s annual list — remains favorable to new and existing businesses, and supports the creation of good jobs. And we need to continually improve the quality of life for our citizens and to be a welcoming place for those who might consider moving here.

The second imperative is a culture change among our companies and our leading academic institutions in terms of how we see one another and how we work together.

In my view, Indiana’s great research universities — public and private — must embrace the notion that one of their prime functions is to actively assist in the process of translating new knowledge into useful products that serve the larger society. We need an infusion of entrepreneurial spirit into our research universities — more people open to pursuing the applications of their research, working collaboratively with others outside their own walls, including industry, and, yes, even starting companies. This is what we see today in San Francisco, in Boston, in San Diego, but not nearly as much as we should here.

Third, we need the active engagement of Indiana state government — which has been supportive, but too often cheering from the sidelines — as an engaged partner with academia and industry in advancing life sciences in Indiana.

The fact is, our top competitors are moving farther ahead, with initiatives like a Massachusetts program that provides $1 billion in state support for biotechnology, including tax incentives to encourage companies to expand, and grants for research, fellowships and workforce training. Now is the time for the State of Indiana to demonstrate in its own way a commitment to the life sciences to answer the challenge of leading competitors like California, Massachusetts, North Carolina — not to mention numerous other cities, regions and countries around the world.

The bottom line? All of the participants in Indiana’s life sciences need to be as innovative in the ways we work together — across disciplines and across institutions — as in the science we pursue.

Now for the bold idea: creating a world-class life sciences research institute in Indiana. This institute will engage entrepreneurial faculty from leading research universities here and around the world — enabling them to work collaboratively with industry to pursue pioneering research in biotechnology, human health and nutrition.

The Broad Institute in Cambridge, Mass.; the Scripps Research Institute in San Diego; and the Danforth Institute in St. Louis are all good examples of research powerhouses that energize a network of life sciences activity in their respective regions.

Finally and importantly, we need a new perspective and a revamped self-image. For too long, Indiana has seemed to be surprised at our success in life sciences, and our ability to compete with the likes of Boston and San Francisco. It’s time to recognize that we’re a leader, to stand tall, and to be content with nothing less than world-class leadership in this 21st Century industry.

As we act with urgency, let’s also act with confidence and boldness, and deliver an effort that’s worthy of the mid-American crossroads of life sciences — Indiana — and chart a course for even greater success and growth. My own company stands ready to participate and to lend its support.

Lechleiter is chairman, president, and chief executive officer of Eli Lilly and Company.

BioCrossroads Announces Venture Competition Winners – Newsroom – Inside INdiana Business with Gerry Dick

October 23, 2012

BioCrossroads Announces Venture Competition Winners – Newsroom – Inside INdiana Business with Gerry Dick.

An Indianapolis-based health IT solutions company has captured first place in BioCrossroads’ inaugural New Venture Competition. Diagnotes LLC has developed a technology to connect providers, patients and patient medical records after regular business hours. The winners were announced as part of the Indiana Life Sciences Summit.

Algaeon Inc. claimed second spot. The Indianapolis company is working on algae production technology for the human the nutraceutical and animal micronutrient markets.

Purdue Research Park-based BioRegeneration Technologies Inc. came in third. The company’s technology is designed to help with cartilage repair.

Two companies have been highlighted in the competitions Pre-Venture category.

NeRx Biosciences Inc. in Indianapolis is developing novel biopharmaceutical compounds for targeted cancer therapeutics.

Sophia Therapeutics is working on customizable therapy for multiple pain states and neuropathies by exploiting specific calcium channels. It is based in Indianapolis.

Source: BioCrossroads


Follow

Get every new post delivered to your Inbox.